Home › Funds › CADIAN CAPITAL MANAGEMENT, LP › BSX
CADIAN CAPITAL MANAGEMENT, LP position in BSX
BOSTON SCIENTIFIC CORP · Health Care
CADIAN CAPITAL MANAGEMENT, LP reported holding 1,105,132 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$47.2M, representing 3.57% of its reported portfolio and ranking #13 among its reported holdings. CADIAN CAPITAL MANAGEMENT, LP has disclosed BSX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How CADIAN CAPITAL MANAGEMENT, LP's BSX position evolved
CADIAN CAPITAL MANAGEMENT, LP first disclosed a stake in BSX in Q1 2026 at 170,000 shares (US$10.7M). The position peaked in Q2 2026 at 1,105,132 shares, worth US$47.2M. Across 2 filings, CADIAN CAPITAL MANAGEMENT, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,105,132 shares valued at US$47.2M — an increase of 935,132 shares quarter over quarter.. Notable position changes include a 550% increase in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 170.00K | $10.67M | New |
| Q2 2026 | 1.11M | $47.17M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- Banque Cantonale Vaudoise 67.61K sh · $2.89B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 50.52M sh · $2.16B · Q2 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
- Bollard Group LLC 18.42M sh · $786.20M · Q2 2026
More on CADIAN CAPITAL MANAGEMENT, LP
FAQ
How long has CADIAN CAPITAL MANAGEMENT, LP held BSX?
CADIAN CAPITAL MANAGEMENT, LP has disclosed BSX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is CADIAN CAPITAL MANAGEMENT, LP's current position in BSX?
As of Q2 2026, CADIAN CAPITAL MANAGEMENT, LP holds 1.11M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $47.17M, representing 3.57% of its reported portfolio and ranking #13.
Has CADIAN CAPITAL MANAGEMENT, LP been buying or selling BSX?
In the latest 13F filing (Q2 2026), CADIAN CAPITAL MANAGEMENT, LP increased its position in BSX. The position peaked in Q2 2026 at 1.11M shares.
Which other funds hold BSX?
Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.